Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients

Vichayanrat, A; Ploybutr, S; Tunlakit, Monchaya; Watanakejorn, Praneet

doi:10.1016/s0168-8227(01)00286-8

Cited by 92 publications

(48 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The addition of α-GI to a DPP-4 inhibitor is an effective diabetes treatment strategy that leads to a 0.3-0.5% HbA1c improvement [16][17][18]. Alfa-GI increases glucagon-like peptide-1 secretion from L cells in the lower duodenum, while DPP-4 inhibitor inhibits glucagon-like peptide-1 degradation, potentiating its hypoglycemic activity, meaning that this combination therapy is quite effective.…”

Section: Discussionmentioning

confidence: 99%

Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients

Tanaka¹,

Nishimura²,

Sekioka³

et al. 2016

J Diabetes Metab

View full text Add to dashboard Cite

Objective: This retrospective cohort study aimed to investigate the significance of dipeptidyl peptidase-4 (DPP-4) inhibitor switch therapy, which is currently not recommended by major diabetes guidelines. Methods:The subjects were 238 outpatients with type 2 diabetes who had been prescribed sitagliptin 50 mg daily, which was subsequently changed in one of three ways. Patients whose sitagliptin was switched to vildagliptin 50 mg twice daily were defined as the switched group. Patients whose sitagliptin was increased to 100 mg once daily were defined as the increased group. Patients who received an additional alfa-glucosidase inhibitor (α-GI) three times daily prior to meals and sitagliptin 50 mg once daily were defined as the added group. The primary endpoint was the glycated hemoglobin (HbA1c) value at 6 months after the medication change. Patients whose oral hypoglycemic agents were changed within 6 months after switching to vildagliptin, increasing sitagliptin, or adding α-GI were excluded from the full analysis set and the remaining patients were included in the per protocol analysis. Results:The per protocol analysis revealed that the HbA1c level decreased significantly in the switched group (n=71) and the added group (n=18) but did not change significantly in the increased group (n=69). Analysis of the full set showed that the HbA1c level decreased significantly in all three groups (switched [n=92], increased [n=88], and added [n=25]).

show abstract

Section: Discussionmentioning

confidence: 99%

Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients

Tanaka¹,

Nishimura²,

Sekioka³

et al. 2016

J Diabetes Metab

View full text Add to dashboard Cite

show abstract

“…The use of α ‐glycosidase inhibitor can delay absorption of carbohydrate through competitive inhibition, thus subsequently inhibit the hydrolysis of disaccharides and the absorption of glucose (Vichayanrat et al. 2002). Research has shown the antidiabetes and antiobesity effects of α ‐glycosidase inhibitor (Elbein, 1991).…”

Section: Introductionmentioning

confidence: 99%

In vitro antidiabetic effects of selected fruits and vegetables against glycosidase and aldose reductase

Luo

2015

Food Science & Nutrition

View full text Add to dashboard Cite

In vitro antidiabetic effect of fruits and vegetables with reports as folk remedies were investigated. The antidiabetic effects were evaluated by comparing the inhibitory properties of α‐glycosidase, aldose reductase, and antioxidant activity. The results indicated that lychee extract exhibited the best dose‐dependent inhibitory activity against α‐glycosidase with IC 50 of 10.4 mg/mL, and lemon peel extract exhibited aldose reductase inhibitory potential with IC 50 value at 3.63 mg/mL. Besides, the result also showed that the inhibitory effects of blueberry and plum against α‐glycosidase were strong among the fruits samples. Bitter gourd and eggplant demonstrated significant inhibitory potential against aldose reductase, with IC 50 values at 8.55 mg/mL and 8.06 mg/mL, respectively. The result from correlation analysis part showed that the antioxidant activities of selected fruits and vegetables were found related to their health beneficial effects, as there was positive correlations between total flavonoids content (TFC) and aldose reductase inhibitory activity (r 2 = 0.556).

show abstract

“…Comparison of the two drugs showed that voglibose use tended to reduce body weight compared with nateglinide but the difference was not statistically significant. The effects of voglibose on body weight has been obscure but it has been reported that this drug effectively reduces body weight [19] or abdominal visceral adipose tissue area in newly diagnosed type 2 diabetes [20].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Adverse Effects of Nateglinide in Early Type 2 Diabetes. Comparison with Voglibose in a Cross-over Study

et al. 2006

View full text Add to dashboard Cite

Abstract. An open-label prospective cross-over trial was performed to compare the efficacy and adverse effects of nateglinide with those of voglibose on Japanese early type 2 diabetes (who were oral hypoglycemic agent naïve and whose HbA 1C levels were between 7.0 and 7.9% before treatment). Fourteen patients received 270 mg/day of nateglinide and 15 patients received 0.6 mg/day of voglibose. After 12 weeks of either therapy, the drugs were switched and treatment was continued for another 12 weeks. After 3-month treatment with each drug, HbA 1C value decreased significantly (baseline HbA 1C 7.24 ± 0.42%, 6.70 ± 0.47% with nateglinide: p<0.01, 6.93 ± 0.62% with voglibose: p<0.05) but the difference in the effect between nateglinide and voglibose was not significant (p = 0.121). Symptoms related to hypoglycemia (e.g., increased appetite, palpitation, sweating, tremor) were scarcely observed with either voglibose or nateglinide treatments. Abdominal fullness/borborygmi was frequently reported, with variable severity, by patients on voglibose but this was absent or mild in those on nateglinide. After completion of both arms of the study, more patients favored nateglinide than voglibose. Our results suggest that nateglinide is an effective and safe drug in the treatment of early type 2 diabetes, similar to voglibose.

show abstract

Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients

Cited by 92 publications

References 10 publications

Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients

Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients

In vitro antidiabetic effects of selected fruits and vegetables against glycosidase and aldose reductase

Efficacy and Adverse Effects of Nateglinide in Early Type 2 Diabetes. Comparison with Voglibose in a Cross-over Study

Contact Info

Product

Resources

About